Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Motor milestone assessment of infants with spinal muscular atrophy using the hammersmith infant neurological Exam—Part 2: Experience from a nusinersen clinical study
Kathie M. Bishop, Jacqueline Montes, Richard S. Finkel
Muscle & Nerve (2017) Vol. 57, Iss. 1, pp. 142-146
Closed Access | Times Cited: 69

Showing 1-25 of 69 citing articles:

Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
Richard S. Finkel, Eugenio Mercuri, Basil T. Darras, et al.
New England Journal of Medicine (2017) Vol. 377, Iss. 18, pp. 1723-1732
Open Access | Times Cited: 1934
One Year of Newborn Screening for SMA – Results of a German Pilot Project
Katharina Vill, Heike Kölbel, Oliver Schwartz, et al.
Journal of Neuromuscular Diseases (2019) Vol. 6, Iss. 4, pp. 503-515
Open Access | Times Cited: 163
Newborn screening for spinal muscular atrophy in Australia: a non-randomised cohort study
Didu Kariyawasam, Arlene D’Silva, Hugo Sampaio, et al.
The Lancet Child & Adolescent Health (2023) Vol. 7, Iss. 3, pp. 159-170
Closed Access | Times Cited: 45
Assessing disease progression in Spinal Muscular Atrophy, current gaps, and opportunities: a narrative review
Robert Muni‐Lofra, Giorgia Coratti, Tina Duong, et al.
Neuromuscular Disorders (2025), pp. 105341-105341
Open Access | Times Cited: 2
Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany
Astrid Pechmann, Thorsten Langer, David Schorling, et al.
Journal of Neuromuscular Diseases (2018) Vol. 5, Iss. 2, pp. 135-143
Open Access | Times Cited: 140
Nusinersen: A Novel Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy
Erin E. Neil, Elizabeth K. Bisaccia
The Journal of Pediatric Pharmacology and Therapeutics (2019) Vol. 24, Iss. 3, pp. 194-203
Open Access | Times Cited: 128
Safety and efficacy of nusinersen in spinal muscular atrophy: The EMBRACE study
Gyula Acsádi, Thomas O. Crawford, Wolfgang Müller‐Felber, et al.
Muscle & Nerve (2021) Vol. 63, Iss. 5, pp. 668-677
Open Access | Times Cited: 91
Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French real-life observational study
Frédérique Audic, M. Gómez García de la Banda, Delphine Bernoux, et al.
Orphanet Journal of Rare Diseases (2020) Vol. 15, Iss. 1
Open Access | Times Cited: 83
Treatment of infantile-onset spinal muscular atrophy with nusinersen: final report of a phase 2, open-label, multicentre, dose-escalation study
Richard S. Finkel, Claudia A. Chiriboga, Jiri Vajsar, et al.
The Lancet Child & Adolescent Health (2021) Vol. 5, Iss. 7, pp. 491-500
Closed Access | Times Cited: 77
Newborn Screening for Spinal Muscular Atrophy in New York State
Bo Hoon Lee, Stella Deng, Claudia A. Chiriboga, et al.
Neurology (2022) Vol. 99, Iss. 14
Open Access | Times Cited: 41
Functional class criteria identification in patients with spinal muscular atrophy 5q
Yu. О. Papina, Е. А. Melnik, Е. Д. Белоусова, et al.
Neuromuscular Diseases (2025) Vol. 14, Iss. 4, pp. 58-70
Open Access | Times Cited: 1
Nusinersen: A Treatment for Spinal Muscular Atrophy
Melanie K. Claborn, Debra L. Stevens, Cheri K. Walker, et al.
Annals of Pharmacotherapy (2018) Vol. 53, Iss. 1, pp. 61-69
Closed Access | Times Cited: 77
Spinal Muscular Atrophy: The Use of Functional Motor Scales in the Era of Disease-Modifying Treatment
Katarzyna Pierzchlewicz, Izabela Kępa, Jacek Podogrodzki, et al.
Child Neurology Open (2021) Vol. 8
Open Access | Times Cited: 44
Disease Modifying Therapies for the Management of Children with Spinal Muscular Atrophy (5q SMA): An Update on the Emerging Evidence
Helgi Thor Hjartarson, Kristofer Nathorst-Böös, Thomas Sejersen
Drug Design Development and Therapy (2022) Vol. Volume 16, pp. 1865-1883
Open Access | Times Cited: 38
Population-based assessment of nusinersen efficacy in children with spinal muscular atrophy: a 3-year follow-up study
Féline E. V. Scheijmans, Inge Cuppen, Ruben P. A. van Eijk, et al.
Brain Communications (2022) Vol. 4, Iss. 6
Open Access | Times Cited: 29
Child Neurology: Pathologically Confirmed Thrombotic Microangiopathy Caused by Onasemnogene Abeparvovec Treatment for SMA
Kotaro Yazaki, Satoru Sakuma, Norikatsu Hikita, et al.
Neurology (2022) Vol. 98, Iss. 19, pp. 808-813
Closed Access | Times Cited: 23
Emerging Gene Therapy Approaches in the Management of Spinal Muscular Atrophy (SMA): An Overview of Clinical Trials and Patent Landscape
Aleksei S. Ponomarev, Daria S. Chulpanova, Lina M. Yanygina, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 18, pp. 13743-13743
Open Access | Times Cited: 16
Treatment Advances in Spinal Muscular Atrophy
Diana Bharucha‐Goebel, Petra Kaufmann
Current Neurology and Neuroscience Reports (2017) Vol. 17, Iss. 11
Open Access | Times Cited: 44
Sitting in patients with spinal muscular atrophy type 1 treated with nusinersen
Karolina Aragon‐Gawinska, Aurore Daron, Ana Ulinici, et al.
Developmental Medicine & Child Neurology (2019) Vol. 62, Iss. 3, pp. 310-314
Open Access | Times Cited: 42
Natural history of Type 1 spinal muscular atrophy: a retrospective, global, multicenter study
Claude Cancès, D. Vlodavets, Giacomo P. Comi, et al.
Orphanet Journal of Rare Diseases (2022) Vol. 17, Iss. 1
Open Access | Times Cited: 20
Assessment of motor function and nutritional status in children with spinal muscular atrophy treated with nusinersen after loading period in Western China: a retrospective study
Hua Yang, Qiuji Tao, Dan Li, et al.
BMC Neurology (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 12
In Search of a Cure: The Development of Therapeutics to Alter the Progression of Spinal Muscular Atrophy
Kristine S. Ojala, Emily J. Reedich, Christine J. DiDonato, et al.
Brain Sciences (2021) Vol. 11, Iss. 2, pp. 194-194
Open Access | Times Cited: 26
The Safety and Efficacy of Nusinersen in the Treatment of Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Kirellos Said Abbas, Mennatullah Mohamed Eltaras, Nahla Ahmed El‐Shahat, et al.
Medicina (2022) Vol. 58, Iss. 2, pp. 213-213
Open Access | Times Cited: 18
A Critical Appraisal of Matching-Adjusted Indirect Comparisons in Spinal Muscular Atrophy
Tammy Jiang, Bora Youn, Angela D. Paradis, et al.
Advances in Therapy (2023) Vol. 40, Iss. 7, pp. 2985-3005
Open Access | Times Cited: 10
Feasibility, Acceptability, and Reliability of Remote Motor Assessment in Children with Canavan Disease
Michael Kiefer, Anzalee Khan, Beth Leiro, et al.
Pediatric Neurology (2025) Vol. 164, pp. 129-136
Closed Access
Page 1 - Next Page

Scroll to top